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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.commore post balloon dilatation and 30-day major stroke in comparison with those treated
by SAPIEN XT (16.1% vs. 7.7%, p¼0.04 and 8% vs. 1.3%, p¼0.02, respectively).
Conclusions: Optimal clinical performance of CoreValve and SAPIEN XT appears to
be reached with different degrees of device oversizing. An individualized-device-
approach during TAVR, utilizing a speciﬁc device for a speciﬁc annulus size, enabling
favorable degree of oversizing, may improve clinical outcomes. This approach should
be further validated in randomized trials.
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Background: TAVR is an alternative to surgery in high risk operable patients;
however, complications and cost currently limit expansion into lower risk populations.
Although mortality, morbidity and length of stay (LOS) are expected to improve, we
sought to determine if a multidisciplinary, multimodality, but minimalist (3M)
approach could improve outcomes with currently available valve technology.
Methods: Patients considered high risk for surgery, but relatively low risk for TAVR,
were rigorously screened with functional and cognitive assessments as well as multi-
modality imaging. From a potential pool of 335 accepted transfemoral TAVR patients,
73 (22%) were selected for the 3M approach and underwent SAPIEN XT (Edwards
Lifesciences Inc., CA, USA) valve implantation. All procedures in the second half of the
cohort (38/73) were performed awake with no sedation and only femoral monitoring.
Thirty day and one year outcomes were reported according to VARC-2 guidelines.
Results: The mean patient age was 837 years with a mean STS score of 8.33.7%.
All-cause mortality or major stroke at 30 days and 1 year was 1.4% (1/73) and 8% (4/
50) respectively. Procedural events at 30 days included life-threatening bleeding
(1.4%), major vascular complications (2.7%), and need for permanent pacemaker
(2.7%). The median LOS was 1 day (IQR1-2) with a mean LOS of 1.71.5 days. The
mean LOS for the initial intubated cohort (35/73) vs the awake cohort (38/73) was
2.12 vs 1.31 days respectively (p¼0.03). Overall, 50/73 (68%) were discharged
home one day post TAVR with 2 readmissions (2.7%) within 30 days. Aortic valve
area increased from 0.70.14 cm2 to 1.690.29 cm2 (p< 0.001) at 30 days and
1.50.25cm2 (p< 0.001) at 1 year; mean trans-aortic gradient decreased from 4318
mmHg to 9  3 mmHg (p < 0.001) at 30 days and 115 mmHg (p < 0.001) at 1 year.
At 30 days and 1 year, 98% (71/73) and 92% (46/50) were NYHA class I or II with
mild or less paravalvular regurgitation.
Conclusions: Rigorous patient screening as well as improvements in procedural
guidance, device selection, and adherence to the 3M clinical pathway permits safe
next day discharge home in high risk patients with a 92% survival rate at 1 year.
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Background: Aortic Valve-in-Valve (VinV) is limited by device underexpansion and
elevated post procedural gradients. Supraanular position of the transcatheter heart
valve (THV) device in relation to the failed surgical valve is suggested to be
advantageous. No comprehensive analysis of implant depth in valve-in-valve and post
procedural hemodynamics was reported.
Methods: Analyses of cases included in the global VinV registry was performed.
Only cases with implantation of either SAPIEN XT or CoreValve were included in
the analysis. Cases performed inside surgical valves without ﬂuoroscopic markers on
bioprosthesis basal ring (e.g. stentless, homografts, Mosaics), or those with subop-
timal images, were excluded. Implant depth was deﬁned in CoreValve cases in
absolute length and in SAPIEN cases in percentage of the THV device below the
surgical valve ring. Evaluation of implantation depth was performed by an analyst
blinded to clinical outcomes. Elevated post procedural gradients were deﬁned as
mean  20mmHg.
Results: A total of 100 aortic vinv cases were analyzed (60% CoreValve, 40%
SAPIEN). Median implanted depth of of the CoreValve device was 7.7mm (inter-
quartile range, IQR, 5.4-10.1mm) and of the SAPIEN device median of 20.3% of
device length below the ring (IQR 7.9-25.5%). Post implantation echocardiographic
results in the total group included: aortic valve area 1.49  0.47cm2, mean gradient 16
 6.9mmHg. Elevated post procedural gradients were recorded in 27% of patients
(16.7% of CoreValve cases, 42.5% of SAPIEN cases). In CoreValve cases implant
depth was strongly associated with elevated gradients (6mm, 22.7%, < 6mm, 0%,
p¼0.04) but not with the surgical valve size (label21mm 17.2%, >21mm 15.6%,
p¼0.34). In SAPIEN cases, association between elevated gradients and surgical valve
size existed (label21mm 66.7%, >21mm 28%, p¼0.02) but not with implant depth
(20% below the bioprosthesis ring, 45%, < 20% below the bioprosthesis ring, 40%,
p¼0.87).
Conclusions: Elevated post-procedural gradients are common after aortic VinV.
Signiﬁcant contributors for elevated gradients are deep implantation of a CoreValve
device and SAPIEN implantation inside a small surgical valve.
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Background: Stroke occurrence in patients undergoing transcatheter aortic valve
implantation (TAVI) has been reported among complications in several studies. The
aim of this study was to assess the impact of periprocedural stroke on mortality at mid-
term follow-up after TAVI.
Methods: Six-hundred-ﬁfty-six patients with aortic stenosis underwent TAVI with the
CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Stroke and
transient ischemic attack were deﬁned according to the Valve Academic Research
Consortium-2 consensus document. A cerebrovascular accident (CVA) was deﬁned as
any stroke or transient ischemic attack. Periprocedural events were deﬁned as events
occurring within 72 hours from the index procedure. Multivariable Cox regression
analyses were performed to calculate hazard ratio (HR) with 95% conﬁdence intervals
(CI) of mortality.
Results: Procedural success occurred in 97.4% of patients. The incidence of any
stroke and of CVA after the index procedure was 2.4% and 2.7%, respectively.
Periprocedural strokes accounted for 56.2% of all strokes and occurred in 1.4% of
patients included in the study. Periprocedural CVA accounted for 55.6% of all CVA
and occurred in 1.5% of patients. After a median follow-up of 434 days, all-cause
mortality and cardiac mortality were signiﬁcantly higher in patients with periproce-
dural stroke as compared to those without (66.7% vs 22.9%, logrank p¼0.001; 66.7%
vs 16.8%, logrank p< 0.001, respectively); and among patients with periprocedural
CVA as compared to those without (70.0% vs 22.8%, logrank p < 0.001; 70.0% vs
16.7%, logrank p < 0.001, respectively). Periprocedural stroke and CVA were sig-
niﬁcant independent predictors of all-cause mortality (HR 4.67, 95% CI 1.96-11.1,
p< 0.001; HR 4.66, 95% CI 2.06-10.5, p< 0.001, respectively) and of cardiac mor-
tality (HR 6.47, 95% CI 2.75-15.2, p< 0.001; HR 6.74, 95% CI 3.05-14.9, p< 0.001,
respectively).
Conclusions: More than half of strokes and CVA following TAVI occur within the
periprocedural period. Periprocedural stroke and CVA are independent predictors of
all-cause mortality and cardiac mortality at mid-term follow-up. Strategies for peri-
procedural cerebrovascular events prevention are needed.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
